One big biotech and two small biotechs especially stand out as attractive picks.
News & Analysis: Ionis Pharmaceuticals
IONS earnings call for the period ending March 31, 2020.
A handful of companies seem immune to fallout from the COVID-19 pandemic. Some may even benefit from it.
IONS earnings call for the period ending December 31, 2019.
The biotechnology company's license fees increased almost 400% to $490 million.
The company is advancing a new treatment for people with Alexander disease.
Both primary as well as multiple secondary endpoints were met in the trial.
The drug will advance to studies in familial chylomicronemia syndrome and other diseases that result in high triglyceride levels.
Investors are overly focused on one issue with this stock while the company is making progress on many fronts.
IONS earnings call for the period ending September 30, 2019.